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The relationship between Hepatitis C Virus (HCV) infection and immunosuppression is complex and multifaceted.
Although HCV-related hepatocytolysis is classically interpreted as secondary to the attack by cytotoxic T
lymphocytes against infected cells, the liver disease is usually exacerbated and more rapidly evolutive in
immunosuppressed patients. This generally occurs during the immunosuppression state, and not at the
reconstitution of the host response after immunosuppressive therapy discontinuation. The field of
immunosuppression and HCV infection is complicated both by the different outcome observed in different
situations and/or by contrasting data obtained in the same conditions, with several still unanswered questions, such
as the opportunity to modify treatment schedules in the setting of post-transplant follow-up. The complexity of this
field is further complicated by the intrinsic tendency of HCV infection in itself to lead to disorders of the immune
system. This review will briefly outline the current knowledge about the pathogenesis of both hepatic and
extrahepatic HCV-related disorders and the principal available data concerning HCV infection in a condition of
impairment of the immune system. Attention will be especially focused on some conditions - liver or kidney
transplantation, the use of biologic drugs and cancer chemotherapy - for which more abundant and interesting
data exist.
Keywords: Hepatitis C Virus (HCV), Hepatic and extrahepatic disorders, Immunopathogenesis of HCV-related
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The relationship between Hepatitis C Virus (HCV) in-
fection and immunosuppression, when compared with
Hepatitis B Virus (HBV) infection, seems quite peculiar.
This is possibly secondary to the differences - both in
structure and replication mechanisms as well as in the
natural history of infection - existing between the viruses.
Although HCV-related hepatocytolysis is classically
interpreted as secondary to the attack by cytotoxic T
lymphocytes against infected cells, the liver disease is
usually exacerbated and more rapidly evolutive in im-
munosuppressed patients. This occurs during the* Correspondence: a.zignego@dmi.unifi.it
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reproduction in any medium, provided the orimmunosuppression state, and not at the reconstitution
of the host response after therapy discontinuation. In
fact, when we compare the average time and range of
years necessary for the establishment of end-stage
chronic liver disease (CLD) under normal conditions
and in various categories of immunocompromised
patients (i.e., transplanted patients, HIV-coinfected sub-
jects, patients with hypogammaglobulinemia), a clear
difference appears, with time intervals ranging from an
average period of 30 years necessary to join the end-
stage CLD in normal conditions to an average interval of
2 years after liver transplantation (LT) [1] (Table 1).
Overall, the varying behavior of the infection in differ-
ent forms of immunosuppression outlines the important
differences between the physiopathology of HCV- or
HBV-related disorders, emphasizing the opportunities
for different approaches and, not least, encouraging al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Time to develop liver cirrhosis in
immunocompetent and immunosuppressed patients
Cathegory of Patients Median/range (years)
Immunocompetent [2,3] 30/13-42
Hypogammaglobulinemia [4-6] 8.8/4.5-15
HIV-HCV co-infection [7-9] 10/6-30
Bone marrow transplantation [10,11] 10.1/1.2-24.9
Liver transplantation [12-14] 2/1-4
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related liver damage.
The field of immunosuppression and HCV infection is
complicated both by the different behavior observed in
different situations and/or by contrasting data obtained
in the same conditions, with several still unanswered
questions, such as the opportunity to modify treatment
schedules in the setting of post-transplant follow-up. The
complexity of this field is further complicated by the in-
trinsic tendency of HCV infection in itself to lead to dis-
orders of the immune system. Of the great variety of
situations leading to immunosuppression in the presence
of HCV infection, the most numerous and interesting
data derive from three conditions which are often inter-
linked: liver or kidney transplantation, the use of biologic
drugs (monoclonal antibodies and interleukins with im-
munosuppressive activity) and cancer chemotherapy. The
complex relationship between HCV and HIV has been
previously deeply developed by others (for review see
[15]) and it will not be the object of the present review.HCV: the burden of chronic infection and mechanisms of
liver disease
HCV infection is a critical public health problem
There are about 200 million HCV carriers worldwide,
more than 100,000 deaths every year are attributable to
HCV and it is estimated that this number will significantly
increase in the future [16]. HCV infection has a high pro-
pensity to persist in the host, in fact, acute infected
patients fail to eradicate the virus in about 80% of cases
and subsequently develop chronic infection. This condi-
tion leads to both extrahepatic and hepatic disorders,
mainly chronic liver inflammation, cirrhosis and liver can-
cer [17]. To persist in the host, HCV uses different strat-
egies aimed at subverting both the innate and adaptive
immune responses. The immune system, in an attempt to
clear the virus, induces continuous and extensive cytolytic
activity on infected hepatocytes resulting in chronic in-
flammation, possibly evolving to severe liver disorders.
The immune-mediated damage, although considered the
main mechanism for HCV-related liver injury, is not ex-
clusive, and a direct viral cytopathic effect has been sug-
gested on the basis of experimental data (see below).Innate immunity
Several lines of evidence indicate that the hepatocytolytic
activity of the immune system is mainly mediated by the
adaptive immunity (for review see [18]). However, compo-
nents of the innate immunity, namely NK and NKT, can
actively participate in the pathogenetic mechanisms by
killing infected cell and, less directly, by the production of
chemokines and cytokines with antiviral and pro-
inflammatory activity as well as by shaping the adaptive
immune response [19]. In HCV infection, a strong inhib-
ition of NK cell response has been documented [20] and
the mechanisms of this impairment could be related to
the effects of E2 protein on the CD81 molecule in NK
cells [21].
Adaptive immune response
Concerning the adaptive immune response, it is well
known that, in the acute phase of infection, a vigorous
and multispecific T cell response is correlated with HCV
clearance, whereas, in patients with chronic infection, the
T cell response is generally delayed, transient and narrowly
focused [22,23]. The dominant role of the adaptive im-
munity in determining the liver injury is confirmed by the
detection of HCV-specific T lymphocytes in the peripheral
blood or in the liver, several weeks after the infection and
in coincidence with the peak of transaminase elevation,
while no cytolytic activity is observed during the massive
viral replication preceding this phase [24]. The depletion
of cytotoxic CD8+ T lymphocytes (CTLs) at the peak of
HCV viremia (and not of the helper CD4+ T cells) signifi-
cantly delays the onset of the biochemical and clinical evi-
dence of hepatitis [18]. Furthermore, the strong
association between the magnitude of HCV-specific CTL
response and the liver disease has been demonstrated both
in chimpanzees and patients with acute and chronic HCV
infection [25].
The analysis of mechanisms of HCV-mediated liver
damage have been mainly focused on the role of CD8+
T lymphocytes due to the effector role of this cellular
component. HCV-specific CD8+ cells exert their action
in limiting viral infection by a dual mechanism: they
contribute to the clearance of infected cells by inducing
apoptosis through the release of cytotoxic granules of
granzyme B that are internalized by the formation of
perforin-induced pores in the hepatocyte membrane.
Granzyme B cleaves pro-caspases which prompts the
caspase cascade that leads to cell apoptosis. In addition,
the activation of the Fas/Fas-ligand pathway leading to
cytochrome C release and Caspase 8 activation has also
been documented [26]. In fact, the overexpression of
Fas molecules on HCV infected hepatocytes has been
detected, as well as the expression of Fas-ligand on the sur-
face of CD8+ T cells infiltrating the liver [27,28]. Besides
their cytotoxic activity, CTLs contribute to the inhibition
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tion, of antiviral cytokines, mainly IFN-γ, as confirmed by
the viral clearance in HCV-infected chimpanzees in the
presence of IFN-γ secreting CTLs, without evidence of
liver disease [29]. Although initiation of the cytopathic ac-
tivity is clearly attributable to HCV-specific CTLs, it is dif-
ficult to explain the amplitude of liver cell destruction as
only secondary to the elimination of HCV-infected cells.
In fact, the number of apoptotic hepatocytes (7-20%
according to the proportion of cells with caspase-3 activa-
tion) seems much higher than the fraction of infected liver
cells (generally estimated in 1-10%) [30]. This discrepancy
could be explained by the so-called “bystander killing” of
hepatocytes not bearing HCV antigens. The number of
HCV-specific CTLs present in the liver is outnumbered by
recruited, HCV-nonspecific, T cells and other inflamma-
tory cells and indeed this number may exceed 90% [31,32].
This additional cell population can contribute to the by-
stander activation. Even though the mechanisms of liver
injury of antigen-nonspecific inflammatory cells are not
fully defined, these include the production and secretion
of proinflammatory cytokines, chemokines and cytotoxic
mediators such as perforin, granzyme B, TNF-α, nitric
oxide, etc. [18].
Besides the previously described role of CTLs, the CD4-
Besides the previously described role of CTLs, the CD4+
helper T lymphocytes play a significant role in the control
of HCV infection and, less directly, in the consequent liver
damage. The central role of helper T cells as regulators of
the immune response includes the facilitation and main-
tenance of virus-specific CTL as well as B-lymphocyte
function and antibody production. Several reports have
shown that a HCV-specific CD4+ T cell response is neces-
sary to activate an effective CTL response and to control
viral infection [33] as also witnessed by the presence, in
patients that resolved HCV infection, of a vigorous, multi-
epitope specific, Th1 type and sustained CD4+ T cell re-
sponse, constantly accompanied by strong CD8+ activa-
tion. Conversely, in chronic carriers, the CD4+ T cell
response was weak, time limited and narrowly selected
[34]. It seems unlikely that helper T lymphocytes play a
major role in liver damage, even if a direct contribution to
liver injury of this cellular component has been hypothe-
sized. However, the magnitude of HCV specific CD4+ T
cell response directly correlates with the rate of progres-
sion of chronic liver disease [35]. It is conceivable that the
helper T cell population could contribute to the pathogen-
etic process with the secretion of soluble factors respon-
sible for the recruitment of inflammatory cells in the liver
and the consequent hepatocellular killing.
Humoral immunity
The role of the humoral immunity in the control of viral
infection and in the pathogenesis of HCV-related liverdamage is controversial. Naturally acquired HCV anti-
bodies cannot protect from reinfection [36,37] and
HCV infection can resolve without developing anti-
HCV antibodies [38]. However, in the chimpanzee
model, it was possible to neutralize HCV infectivity by
in vitro treatment with antibodies taken from chronically
infected HCV patients [39]. The existence of neutralizing
antibodies was confirmed by several studies and the inef-
fectiveness in protecting from reinfection probably
reflects the sensitization to virions that were counterse-
lected and have been substituted by mutated viral species
escaping the immune response. The possible contribu-
tion of antibodies, or even B cells, to liver damage is still
being debated and indisputable results are lacking [40].
However, chronic HCV infection leads to autoimmune/
lymphoproliferative disorders (see also below) and the
tissue damage secondary to HCV-induced immune com-
plexes has been largely documented (for review [41]).
Direct viral activity
Besides the previously described role of the immune sys-
tem in the pathogenesis of HCV-related liver disease, a
direct action of the virus has been proposed. HCV pro-
teins (mainly core and NS5) have been shown to play a
pathogenetic role in inducing oxidative stress in hepato-
cytes (for review see [42]). HCV core has been associated
with the induction of lipid droplet accumulation and
favoring of liver steatosis [43,44]. A direct oncogenetic
effect of some HCV proteins has also been reported and
may be involved in hepatocarcinogenesis. In fact, HCV
core, NS3 and NS5A have been demonstrated, in vitro,
to alter cell proliferation and apoptosis through different
mechanisms including the activation of transcription
factors, modulation of protoncogenes, inhibition of pro-
grammed cell death, interference with tumor suppressor
proteins (for review see [45]).
HCV and lymphoproliferative disorders
Early after its discovery, it was shown that HCV is also a
lymphotropic virus [46]. As a consequence of the lymph-
atic infection, several lymphoproliferative disorders
(LPDs) have been associated with HCV infection [47],
including mixed cryoglobulinemia (MC) and B-cell non-
Hodgkin's lymphoma (B-NHL) [48-59].
Mixed cryoglobulinemia, is a clinically benign, but
pre-lymphomatous disorder, evolving in about 10% of
cases, into a malignant lymphoma [41,47,60]. Therefore,
it was hypothesized that HCV may be involved in the
pathogenesis of B-NHL as well [46,49,54]. This hypo-
thesis was substantiated by several observations includ-
ing the significantly high prevalence of HCV infection in
NHL patients, [51,52,54,58,59,61-65] - even with a higher
prevalence in Southern countries - as well as the possible
resolution of the disease following viral eradication [66].
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HCV-infected patients observed during a long-term fol-
low-up, it was shown that the annual incidence of lymph-
oma was 0.23% and the cumulative rate of lymphoma
development after 15 years was 2.6% in both the un-
treated and non-responder patients with persisting in-
fection versus 0% in treated patients achieving viral
eradication, strongly suggesting that the viral eradication
protects against the development of lymphoma [67]. Sev-
eral histopathological types of lymphoma have been
observed in HCV patients, the most strictly associated
being the lymphoplasmacytic, marginal zone and diffuse
large B-cell lymphoma, as also shown in a recent very
large multicenter study [68].
Interestingly, the de novo appearance or exacerbation
of HCV-related LPDs have been shown in conditions of
persisting immunosuppression, like the liver transplant-
ation [69-71].Mechanisms of lymphomagenesis
Sustained antigenic stimulation
Several hypotheses have been proposed concerning the
possible mechanisms of HCV lymphomagenesis. First,
sustained antigenic stimulation has been suggested to
play a key role in inducing the B-cell clonal expansion
characterizing these disorders and it has been suggested
that the same HCV antigens may be involved in the in-
duction of both MC and lymphoma [72,73]. In other
studies it has been suggested that HCV E2 and NS3 pro-
teins represent the involved antigens. Particular atten-
tion was focused on the E2 protein. It has been shown
that E2 interacts with the tetraspannin CD81, present
also on the B-cell surface and it has been suggested that
this binding is responsible for a sustained polyclonal B-
cell activation essentially by lowering the B-cell activa-
tion threshold [74,75]. In addition, E2 protein has been
suggested to be the inciting antigen of HCV-related
NHL [76]. A specific expression of particular VH genes
(VH1-69) in MC monoclonal B-cells has been demon-
strated [77] and an accelerated apoptosis and marked
anergy of these cell populations in MC patients have
been recently reported [78,79]. Several studies have sug-
gested that some cytokines, including IL-1, IL1 inhibi-
tors and some chemokines, play a role [80-82]. Among
these, particular attention has focused on B-cell activat-
ing factor (BAFF or BLyS). High levels of this cytokine
were shown in patients with HCV-related autoimmune
and/or LPDs and especially in MC [83]. We have investi-
gated the reasons for such elevated levels and shown
that MC patients were characterized by a higher preva-
lence of a particular allele of the gene promoter previously
shown to be associated with enhanced transcriptional ac-
tivity. Furthermore, T homozygosis was associated withsignificantly higher levels of the cytokine in the patients’
serum [84].Viral lymphotropism
Conflicting data are available concerning the lymphatic
infection in patients with LPDs, probably due to tech-
nical difficulties. However, some data are of interest,
starting from the observation of a more evident infection
of peripheral blood mononuclear cells (PBMC) in pa-
tients with MC than in patients without [49]. In a study
using the model of injection of PBMC from HCV-
positive patients into SCID mice, it was shown that the
samples derived from HCV patients with malignant LPDs
were characterized by positivity for HCV replicative in-
termediates, stronger signals when tested for HCV gen-
omic sequences and successful serial passage of infected
cells in different animals [85]. More recently, Sung and
coworkers showed the establishment of B-cell lines per-
sistently producing infectious virus from an HCV-positive
lymphoma [86]. Finally, using a model of in vitro HCV
infection of B-cells, it was possible to show that this in-
fection may induce an enhanced mutation rate of immu-
noglobulins and some oncogenes, possibly through the
induction of error-prone DNA polymerase and AID, sug-
gesting that HCV may cause tumors by a hit and run
mechanism [87]. More recently, Ito and coworkers ob-
served a dramatically increased expression of AID in the
B-cells of HCV patients, suggesting that this may repre-
sent a key lymphomagenetic factor [88].Direct activity of viral proteins
In regard to viral proteins, particular attention has been
focused on the HCV core protein due to previously
shown pleiotropic effects on different cell signaling
pathways modulating cell viability and proliferation
[45]. Focusing on animal models, core transgenic mice
developed lymphoma with high frequency [89]. In an-
other transgenic model, the expression of the HCV core
in the context of all structural proteins and in a irf −/−
background, was associated with the development of
lymphoid disorders including frank lymphoma [90].
More recently, the expression of the whole HCV gen-
ome in the B-cell compartment resulted in a high
prevalence of diffuse large B-cell lymphoma [91]. Inter-
estingly, the HCV core gene was expressed in all
lymphomas. Finally, in a study performed on both B-
cell lines expressing the HCV core protein and in pri-
mary B-cells from patients with LPDs, it was possible
to show the altered expression of some isoforms of
genes of the p53 family, the DNp63 and DNp73, previ-
ously shown to be overexpressed in human cancers, in-
cluding lymphoma [92].
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Interesting data also exist about the possible role played
by chromosomal aberrations, the most studied being the t
(14;18) translocation. This translocation was found to be
significantly associated with type II or monoclonal MC
and the overexpression of the antiapoptotic bcl2 gene in
B-cells, resulting in an imbalance of the Bcl2/Bax ratio
and abnormal B-cell survival [93-96]. The regression of
the expanded B-cell clones following effective antiviral
treatment and, in some relapsing patients, a new expan-
sion of the same clones was also shown [97]. Finally, in a
long-term follow-up study, an occult HCV persistence
limited to the lymphatic compartment was observed in
some patients resulting sustained virological responders
after antiviral therapy [98,99]. More interestingly, such a
persistent occult lymphatic infection was associated with
the initial diagnosis of MC, the persistence of some MC
symptoms after therapy and of expanded translocated B-
cell clones. The occurrence, even if rare, of persisting MC
disease, in spite of complete viral eradication, suggests the
existence of points of no return [98,99]. The high preva-
lence of t(14;18) in HCV-related MC was shown by differ-
ent authors using various methodological approaches
including PCR-based methods, sequencing and fluores-
cence in situ hybridization with probes [93-96,100,101].
Contrasting data were also reported, probably due to dif-
ferent methodological approaches. Sansonno and cowor-
kers could not show the same frequency of bcl-2
rearrangement by performing PCR assays on nucleic acids
extracted from portal tract isolated with laser capture
microdissection from liver biopsy sections of 16 HCV
patients with and without extrahepatic B cell-related dis-
orders [102].
In conclusion, available data suggest that HCV lym-
phomagenesis is a complex multistep multifactorial pro-
cess, probably based on sustained B-cell activation and
the inhibition of B-cell apoptosis on a background of
genetic predisposing factors and evolving through the
progressive addition of genetic aberrations which allow
the process to be progressively less dependent on the
etiologic agent.
Overall, the pathogenesis of HCV-related hepatic and
extrahepatic disorders (the so-called “HCV disease”) is
still not completely known. In particular, the relationship
between this infection and the immune system appears
very complex and multifaceted. In this light, the analysis
of the “in vivo” effects of a condition of general or vari-
ably selective impairment of the host’s immune response
should evidence very interesting models of study, possibly
helping to clarify still unclear pathogenetic mechanisms
with high translational potentiality in the clinical approach
to this complex condition.
The following sections will focus on the main available
data concerning some conditions which are the principalsource of information on the effects of immunosuppres-
sion in the presence of HCV infection, and which are
often interlinked: liver or kidney transplantation, the use
of some biologic drugs and cancer chemotherapy.
HCV infection and transplantation
Liver transplantation
The field of liver transplantation (LT) has been well
investigated and provides ample data about the effect of
immunosuppression on HCV-related disease [103], even
if the liver transplanted patient does not appear an opti-
mal model. This appears secondary to the variety of pro-
tocols used in different studies and the many variables
involved, accounting for the non-uniformity in conclu-
sions from different studies.
A common observation is that, in the case of LT for
HCV-related disease, reinfection of the graft is almost
immediate and universal, and the progression of liver
damage is five- to ten-fold faster compared to non-
transplanted patients, so that up to 40% of patients ex-
perience recurrent hepatitis and cirrhosis 5 years later
[104]. The accelerated course of post-transplant hepatitis
C translates into a significantly higher rate of graft loss
[105]. In addition, liver transplantation appears to be
relevant also with reference to HCV LPD pathogenesis.
As an example, de novo appearance or exacerbation of
MC has been reported after LT, even if the involved
mechanisms are still unclear [69-71].
The main differences consist in the interpretation of
the role played by immunosuppressive drugs -especially
corticosteroids (CS) and cyclosporin A (CsA) - used in
the post-LT period, with different suggested therapeutic
protocols.
An explanation for the hypothesis of different effects
on recurrent HCV-related liver damage after LT using
CS - or CsA - based protocols, can be found in recent
studies performed in vitro using the replicon system and
showing that - unlike what is known in the case of HBV -
CS does not act by increasing viral replication, but by
dramatically increasing the ability of HCV to enter into
target cells and thus spread the infection through the
transactivation and consequent overexpression of genes
codifying for HCV cellular receptors (occludin, SR-B1)
[106,107]. A recent report evaluating the safety and effi-
cacy of steroid-free immunosuppression, showed that
this approach is safe and effective for liver transplant
recipients with chronic HCV, however, steroid sparing
has no clear advantage in comparison with traditional
immunosuppressive protocols [108]. Several studies have
reported the antiviral effect of CsA. In fact, HCV is critic-
ally dependent on cyclofilin B to complete its intracellu-
lar replication. Consequently, the binding of cyclosporin
A with cyclofilin B leads to the suppression of HCV rep-
lication. This suggests a clinical advantage in using CsA
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tors of calcineurin (CNIs), but they act through a differ-
ent mechanism since TAC acts through FKBP12 (for
review see [110,111]) and does not have any antiviral ef-
fect [106].
There are numerous clinical studies reporting con-
flicting outcomes with each of the different immunosup-
pressive drugs used in the post-transplant period which
condition the rapidity of liver damage progression. In
spite of varying conclusions from different studies
regarding the effect of CS avoidance on recurrent hepa-
titis C, a meta-analysis of the available randomized trials
indicates that the relative risk of HCV recurrence
reached statistical significance (p= 0.03) for a better out-
come with CS avoidance [112]. In addition, there is gen-
eral agreement about including treated episodes of acute
cellular rejection and pulse therapy with CS, as well as
longer duration/higher cumulative exposure to CS, among
the factors which highly influence the negative impact of
liver transplantation in HCV + patients [113-115]. These
data suggest that the benefit of CS avoidance may be real,
even if small. Because CS is not required for successful
LT and its use is associated with several side effects, it
has been suggested that CS minimization or avoidance
would be an important practice in HCV patients [116].
Conflicting results are also reported for the use of CsA
instead of TAC. In most retrospective studies, no differ-
ence was apparent [117-120]. In a meta-analysis, statisti-
cally significant differences between TAC-based vs. CsA-
based therapies were not found for mortality, graft sur-
vival and fibrosing cholestatic hepatitis [121]. In a more
recent prospective, randomized trial, no differences were
found between the 136 patients allocated to CsA and the
117 on TAC [122].
A recent report, based on data received from the Uni-
ted Network for Organ Sharing, describing a very large
cohort of 8809 chronic HCV liver transplant recipients,
showed an increased risk of patient death and graft fail-
ure in CsA treated patients compared to TAC treated
patients, suggesting to reconsider the targeted adminis-
tration of CsA to HCV-infected liver transplant recipi-
ents [123]. However, in a multicenter study, the mean
time to histological diagnosis of hepatitis C recurrence
was significantly longer with CsA [124].
A beneficial impact of Sirolimus (RIR) on HCV recur-
rence was also suggested [125]. Interestingly, Sirolimus
is becoming a relevant player in iatrogenic immunosup-
pressed patients to avoid HHV8 reactivation with conse-
quent high risk of Kaposi sarcoma incidence. However,
these data require further confirmation [126]. On the
whole, immunosuppression determines HCV-related dis-
ease progression; however the effects of different im-
munosuppressive drugs used after transplantation (such
asCNIs,CS,mycophenolatemofetyl -MMF-,azathioprine)on HCV recurrence are still equivocal and there are no
convincing data to modify the currently used type of im-
munosuppression. At present, the only form of immuno-
suppression which has been undoubtedly and consistently
associated with more severe hepatitis C recurrence is the
treatment of acute cellular rejection, a condition that is
typically treated with pulse CS or biological drugs
(OKT3, thymoglobulin) [104,114,127]. Consequently, it
is recommended to avoid steroid boluses. Furthermore,
since insulin resistance and diabetes are associated with
fibrosis in HCV-infected liver recipients, the use of im-
munosuppressive agents without this side effect may
slow post-LT disease progression [128,129]. Prospective
controlled studies aimed at definitely resolving these still
unresolved questions are ongoing.
Kidney transplantation
Similar considerations may be translated into the less
documented field of kidney transplantation in HCV-
positive patients. Whereas a series of past studies includ-
ing short-term follow-up post-transplantation suggested
that there was no significant difference between HCV-
positive or -negative patients, the existence of such a dif-
ference was shown to become significant after 5 years
post-transplantation in studies including longer follow-
up [130]. In the study by Fabrizi et al. [131] the meta-
analysis of several observational studies showed that the
survival of the transplanted organ was lower in HCV-
positive patients and that the higher mortality rate was
related to the increase in viral replication/liver damage.
HCV infection and biological drugs
The effects of biological drugs on HCV infection and its
sequelae are particularly interesting. A consistent amount
of data exists about the anti-TNF agents (i.e., etanercept,
infliximab, adalimumab). In a recent review by Ferri
et al., anti-TNF drugs result in being effective and well
tolerated in the case of HCV-positive patients. The pos-
sible positive effect exerted by the inhibition of TNF-α
(reputed to play a key role in the pathogenesis of HCV-
related liver damage) is outlined in some studies and the
possible efficacy of combined therapies, including both
anti-TNF-α and standard anti-HCV treatment, has been
suggested [132].
Of the biological drugs used in the treatment of HCV-
positive patients, increasing interest during the last dec-
ade has been focused on the anti-CD20 monoclonal
antibody rituximab (RTX), a B-cell specific immunosup-
pressant acting through transient depletion of the B-cell
compartment. The use of RTX, initially confined to the
onco-hematological area, has been progressively expanded
to involve a growing number of autoimmune and benign
B-cell lymphoproliferative conditions. Due to the etio-
pathogenetic role played by HCV in several autoimmune
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effects of RTX in HCV-positive patients are of special
interest. Patients undergoing RTX therapy for HCV-
related MC appear to be a unique model of study. Begin-
ning with pioneering studies in 2002–2003 [133-135],
RTX has been shown to be efficacious in the treatment
of the majority of MC symptoms and valuable in patients
in whom antiviral therapy was contraindicated [40,132].
However, the observation of especially severe hepatitis
reactivations after RTX use in HBV-positive patients, has
justified the exclusion of also HCV-positive MC patients
with advanced liver disease also. However, in two succes-
sive studies, it was possible to observe that RTX was use-
ful and safe in MC patients with HCV-related advanced
liver disease [40,136]. Interestingly, in these patients the
treatment induced an unexpected, paradoxical positive
effect on the liver disease. This was especially evident in
cirrhotic patients with ascitic decompensation who
experienced a consistent improvement of cirrhotic syn-
drome, including the disappearance of the ascites in
some cases, improvement of protido-synthetic activity of
the liver with increasing levels of plasmatic albumin, and
a reduction of the Child-Pugh score. Viremia titers tran-
siently increased and hepatocytolysis followed the pro-
gressive reconstitution of the B-cell compartment. On
the whole, the average level of ALT did not increase
[134]. These effects of RTX therapy [40], and the rapidity
of their appearance following B-cell depletion, strongly
suggested a consistent role played by modifications in
the cytokine network and a previously unknown key role
played by B-cells in the pathogenesis of HCV-related
liver damage [40].
Apart from the consequences of the use of specific
biological drugs, it is generally agreed that the risk re-
lated to a reactivation of hepatitis C in patients with
autoimmune/rheumatological conditions treated with
current immunosuppressive drugs, is of a consistently
lesser extent than in the case of hepatitis B and generally
associated with the use of combinations of different im-
munosuppressant agents.
HCV infection and chemotherapy
Another complex issue involves the effect of HCV infec-
tion on patients undergoing chemotherapy. It is well
known that in the case of patients with HBV infection,
the most critical condition is represented by hematologic
malignancies. In this field, some past studies have
strongly suggested that chemotherapy generally does not
have dramatic consequences: it is possible that liver
damage occurs, but severe consequences have to be con-
sidered as rare events [137]. More recently, the study by
Mailliard and coworkers offered a unique possibility to
evaluate the impact of chemotherapy on oncology
patients [138]. This study was based on the analysis ofthe long-term follow-up of victims of a nosocomial epi-
demic by the same strain of HCV G3a, in patients with
either hematological or solid-tumor cancer undergoing
chemotherapy. In this study, 100% of cases become
chronic and developed severe liver damage (cirrhosis)
over a very limited time, with significant mortality.
Recently, a review of the available literature revealed
that, in the case of patients with hematological malig-
nancies, the presence of HCV infection is associated
with increased risk for sinusoidal obstruction syndrome
(SOS), graft versus host disease (GVHD) and liver fail-
ure, but does not affect short-term survival in bone mar-
row transplant (BMT) recipients. So, infection with
HCV in donor or recipient should not be considered an
absolute contraindication for BMT [139].
More recently, several case reports or retrospective
studies have outlined the potential risk of hepatitis C re-
activation following regimens including chemotherapy
and RTX in HCV-positive lymphoma patients. When
compared with the above cited effects of RTX monother-
apy on a HCV-related benign lymphoproliferative disorder
(MC) these recent data suggest more serious effects on
viral replication and ALT flares in oncohematological
patients [140-143]. Despite the paucity of available data as
well as the existence of some more reassuring results from
different studies, it seems conceivable that situations in-
volving both a baseline immunosuppressive status - linked
to the oncohematological condition - and a combination
of different immunosuppressive drugs, may result in a
varying, more aggressive evolution of liver damage. While
waiting for more consistent data, a recent meta-analysis of
available studies concludes that even in such situations,
the presence of infection should not be considered a
contraindication to the use of therapies based on RTX, es-
pecially in patients without initial liver dysfunction.
Overall, the current data appear insufficient to draw
definitive conclusions regarding the effect of HCV viral
load, reactivation, and treatment on the prognosis of
cancer, and especially in patients with lymphoma.
Conclusions
Liver disease in an immunosuppressed patient is typic-
ally severe with an unusually rapid progression to cirrho-
sis. However, the combination of HCV infection and
immunosuppression may lead to different conditions
ranging from enhancement to inhibition of HCV replica-
tion/infection and from worsening to improvement of
liver damage. These possibilities should be accurately
evaluated in each patient, taking into consideration vari-
ables such as the type of immunosuppression and the
baseline liver damage/pathological condition to be trea-
ted. These characteristics make the study of this situ-
ation very promising in the field of immunopathogenesis
of both hepatic and extrahepatic HCV-related diseases.
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rapidly evolving, difficult-to-control liver disease appears
to be lower than in the case of HBV infection and so a
less cautious approach is allowed if immunosuppressive
therapy is considered urgent and necessary. However,
accurate screening and specialized advice is recom-
mended as soon as possible in HCV-positive patients.
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